Sökning: "Klinisk minnesforskning"

Visar resultat 1 - 5 av 23 avhandlingar innehållade orden Klinisk minnesforskning.

  1. 1. The future of clinical trials for Alzheimer's disease. A blood-based biomarker perspective

    Författare :Nicholas Cullen; Klinisk minnesforskning; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Alzheimer s disease; Biomarkers; Cognition; Amyloid; Tau; Neurodegeneration;

    Sammanfattning : Objectives: The primary objective was to investigate the utility of blood-basedbiomarkers of amyloid, tau, and neurodegeneration for (i) screening, (ii)enrichment, and (iii) tracking response to treatment in clinical trials of Alzheimer’sdisease.Methods: Longitudinal, participant-level data used in these studies was drawn fromthe Swedish BioFINDER study and the ADNI study. LÄS MER

  3. 2. Long Term Outcome and Prediction Models of Cognition, Activities of Daily Living and Nursing Home Placement in Alzheimer’s Disease with Cholinesterase Inhibitor Treatment

    Författare :Carina Wattmo; Klinisk minnesforskning; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; longitudinal studies; nursing home placement; activities of daily living; cognition; Alzheimer s disease; cholinesterase inhibitors; disease progression; predictors; statistical models.;

    Sammanfattning : Background Prospective longitudinal studies in Alzheimer's disease (AD) that include cholinesterase inhibitor (ChEI) treatment in routine clinical settings are scarce. The patients vary in severity of the disease, clinical course, rate of progression and response to treatment. LÄS MER

  4. 3. Validation of brief cognitive tests in mild cognitive impairment, Alzheimer's disease and dementia with Lewy bodies

    Författare :Sebastian Palmqvist; Klinisk minnesforskning; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Cognitive tests; neuropsychology; Alzheimer’s disease; dementia with Lewy bodies; mild cognitive impairment; treatment evaluation; acetylcholinesterase inhibitors; differential diagnosis; longitudinal studies; dementia; cerebrospinal fluid; forecasting;

    Sammanfattning : Background It is estimated that 34 million people suffer from dementia, costing society US$422 billion each year. Alzheimer’s disease (AD) is the most common dementia and the global prevalence is predicted to increase to over 100 million people by the year 2050, with the greatest increase in developing countries. LÄS MER

  5. 4. Markers of Prognosis in Neurodegenerative Dementia

    Författare :Kajsa Stubendorff; Klinisk minnesforskning; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Lewy body disease; Alzheimer s disease; dementia with Lewy bodies; prognosis; survival; longitudinal studies; biomarkers; cerebrospinal fluid; dysautonomic orthostatic hypotension; memantine;

    Sammanfattning : Background: A prognostic marker should provide information about course and outcome of disease, e.g. predict time to a given endpoint or rate of progression due to disease in patients or subgroups of patients. Prognostic markers could be targeted to apply during the entire clinical course or just during distinct stages of the disease. LÄS MER

  7. 5. Pathophysiological Mechanisms and Diagnostic Markers in Alzheimer’s Disease

    Författare :Joakim Hertze; Klinisk minnesforskning; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Alzheimer’s disease; mild cognitive impairment; white matter lesions; brain reserve; blood-brain barrier; angiogenesis; neuroinflammation; neurogranin; YKL-40; VEGF; IGF; ICAM-1; VCAM-1;

    Sammanfattning : Alzheimer’s disease (AD), the most common cause of dementia, is a growing concern. As the life expectancy increases across the globe, the number of affected people is estimated to reach 100 million by 2050. LÄS MER